Treating Autism With Bumetanide: Are Large Multicentric and Monocentric Trials on Selected Populations Complementary?
- PMID: 33385505
- DOI: 10.1016/j.jaac.2020.09.025
Treating Autism With Bumetanide: Are Large Multicentric and Monocentric Trials on Selected Populations Complementary?
Abstract
In their article in the Journal, Sprengers et al.1 conclude that bumetanide does not attenuate autism spectrum disorder (ASD) despite a nominally significant treatment effect in repetitive behaviors, which is a core symptom of ASD but was defined as a secondary measure in this trial. Four earlier studies performed by 3 independent institutes, including 2 studies2,3 not mentioned by Sprengers et al., testing a total of 169 children (versus 122 placebo) showed a significant amelioration of ASD symptoms. Bumetanide also significantly attenuated behavioral features of patients with tuberous sclerosis according to another study by Sprengers' same group.4.
Copyright © 2021 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.
Comment in
-
Dr. Sprengers et al. Reply.J Am Acad Child Adolesc Psychiatry. 2021 Aug;60(8):938-939. doi: 10.1016/j.jaac.2020.12.034. Epub 2021 Jan 12. J Am Acad Child Adolesc Psychiatry. 2021. PMID: 33450401
Comment on
-
Bumetanide for Core Symptoms of Autism Spectrum Disorder (BAMBI): A Single Center, Double-Blinded, Participant-Randomized, Placebo-Controlled, Phase-2 Superiority Trial.J Am Acad Child Adolesc Psychiatry. 2021 Jul;60(7):865-876. doi: 10.1016/j.jaac.2020.07.888. Epub 2020 Jul 27. J Am Acad Child Adolesc Psychiatry. 2021. PMID: 32730977 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
